What is the recommended whole-body low-dose Computed Tomography (CT) protocol for initial staging and follow-up in patients with multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Whole-Body Low-Dose CT Protocol for Multiple Myeloma

Whole-body low-dose CT (WBLDCT) is the recommended primary imaging modality for initial diagnosis and follow-up of multiple myeloma, extending from skull vertex to knees without intravenous contrast, with radiation doses of 3.2-4.8 mSv. 1

Technical Parameters for WBLDCT Protocol

  • Detector configuration: 80×0.5 mm 2
  • Scanning range: Single spiral acquisition from skull to proximal femoral bones 2
  • Tube voltage: 120 kVp 2, 3
  • Tube current time product: 40-86 mAs (can be adjusted based on patient size) 2, 3
  • Slice thickness: 1 mm 2
  • No intravenous contrast (should be avoided in myeloma patients) 1
  • Expected radiation dose: 4.1-4.8 mSv (compared to 2.4 mSv for conventional skeletal survey) 1, 3

Image Reconstruction Parameters

  • Two sets of axial images should be reconstructed 2, 3:
    • Bone assessment (high-resolution algorithm)
    • Soft tissue assessment (standard algorithm)
  • Secondary coronal and sagittal reconstructions should be generated 2
  • Middle-frequency reconstruction algorithm (B50f kernel) is beneficial for all energy protocols 3

Clinical Application in Multiple Myeloma

  • WBLDCT is designated as "obligatory" for initial diagnosis of multiple myeloma according to EHA-ESMO guidelines 4
  • WBLDCT detects 25.5% more lesions than conventional skeletal surveys, particularly in spine and pelvis 1
  • For follow-up after treatment, WBLDCT is recommended when patients become symptomatic 4
  • NCCN guidelines recommend either WBLDCT or FDG-PET/CT for initial diagnostic workup 4, 1

Advantages Over Conventional Skeletal Survey

  • Superior detection of osteolytic lesions in areas difficult to visualize with skeletal surveys (skull, ribs, spine, pelvis) 1, 5
  • Prospective studies show WBLDCT identifies more bone lesions per patient (8.2 vs 3.6 with skeletal survey) 5
  • Faster scanning time and higher resolution images for proper management of MM patients 6
  • Can detect extraosseous findings including pleuro-pulmonary lesions 6

Comparison with Other Imaging Modalities

  • If PET/CT is used instead of WBLDCT, the CT component should have imaging quality equivalent to WBLDCT 1
  • MRI is particularly useful when WBLDCT is negative, especially for discerning smoldering myeloma from active disease 1
  • WBMRI has higher sensitivity for detecting focal and diffuse plasma cell infiltration patterns before osteolytic destruction 7

Follow-up Recommendations

  • The same imaging modality used during initial workup should be used for follow-up assessments for consistency 1
  • Assessment frequency should be at minimum every 3 months during active treatment 1
  • For relapse assessment, WBLDCT is recommended when patients become symptomatic 4

Common Pitfalls and Caveats

  • Image quality may be reduced in patients with diffuse skeletal infiltration or concurrent osteoporosis 3
  • Non-isotropic voxel size may limit the quality of multiplanar reformatted images compared to axial images 3
  • Small arachnoid granulations can be misinterpreted as lytic lesions on skull radiographs but are correctly identified with CT 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.